Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of γH2AX foci

Molecular Cancer Therapeutics

Volumn 3, Issue 4, 2004, Pages 409-416

  Camphausen, Kevin ^a   Brady, Kristin J ^a   Burgan, William E ^a   Cerra, Michael A ^a   Russell, Jeffrey S ^a   Bull, Elizabeth E A ^a   Tofilon, Philip J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Radiation Oncology Sciences Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA; FLAVOPIRIDOL; HISTONE; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DATA ANALYSIS; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; DNA REPAIR; FLAVONOIDS; HISTONES; HUMANS; PHOSPHORYLATION; PIPERIDINES; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; RADIATION TOLERANCE; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II;

EID: 4444282904     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Senderowicz A, Sausville E. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst, 2000;92: 376-87.
2. Senderowicz A, Headlee D, Stinson S, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol, 1998;16:2986-99.
3. Losiewicz M, Carlson B, Kaur G, Sausville E, Worland P. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun, 1994;201:589-95.
4. Carlson B, Dubay M, Sausville E, Brizuela L, Worland P. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma lines. Cancer Res, 1996;56: 2973-8.
5. Sedlacek H, Czech J, Naik R, et al. Flavopiridol (L86-8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol, 1996;9: 1143-68.
6. Chao S, Fujinaga K, Marion J, et al. J Biol Chem, 2000;275:28345-8.
7. Chao S, Price D. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem, 2001;276:31793-9.
8. Lam L, Pickeral O, Peng A, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol, 2001;2:1-11.
9. Wittmann S, Bali P, Donapaty S, et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to Epothilone B-induced apoptosis. Cancer Res, 2003;63:93-9.
10. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res, 1999;59:4634-41.
11. Bible K, Bible R, Kottke T, et al. Favopiridol binds to duplex DNA. Cancer Res, 2000;60:2419-28.
12. Thomas J, Tutsch K, Cleary J, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol, 2002;50:465-72.
13. Tan A, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol, 2002;20: 4074-82.
14. Bible K, Kaufmann S. Cytotoxic synergy between flavopiridol (NSC 64890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res, 1997;57: 3375-80.
15. Jung C, Motwani M, Schwartz G. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res, 2001;7:2527-36.
16. Nahta R, Iglehart J, Kempkes B, Schmidt E. Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between Herceptin and Flavopiridol. Cancer Res, 2002;62:2267-71.
17. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz G. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther, 2003;2:549-55.
18. Nahta R, Trent S, Yang C, Schmidt C. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res, 2003;63: 3626-31.
19. Schwartz G, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol, 2002;20:2157-70.
20. Raju U, Nakata E, Mason K, Ang K, Milas L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res, 2003;63:3263-7.
21. Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C, Stadler W. in vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol, 1999;44:81-7.
22. Voskoglou-Nomikos T, Pater J, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res, 2003;9:4227-39.
23. O'Brien M, Healy S, Raney S, et al. Discrimination of late apoptotic/necrotic cells (type III) by flow cytometry in solid tumors. Cytometry, 1997;28:81-9.
24. Xu B, Kim S, Lim D, Kastan M. Two molecularly distinct G2/M checkpoints are induced by ionizing irradiation. Mol Cell Biol, 2002;22: 1049-59.
25. Russell J, Raju U, Gumin G, et al. Inhibition of radiation-induced nuclear factor-κB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res, 2002; 62:2318-26.
26. Bookstein R, Shew J, Chen P, Scully P, Lee W. Suppression of tumorigenicity of human prostate carcinoma cell by replacing a mutated RB gene. Science, 1990;247:712-5.
27. Gojo I, Zhang B, Fenton R. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res, 2002;8: 3527-38.
28. Kao G, McKenna G, Yen T. Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells. Oncogene, 2001;20: 3486-96.
29. Xu B, Kim S, Kastan M. Involvement of Brca1 in S-phase and G2-phase checkpoints after ionizing irradiation. Mol Cell Biol, 2001;21: 3445-50.
30. Rogakou E, Pilch D, Orr A, Ivanova V, Bonner W. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem, 1998;273:5858-68.
31. Sedelnikova O, Rogakou E, Panyutin I, Bonner W. Quantitative detection of (125)ldU-induced DNA double-strand breaks with γ-H2AX antibody. Radiat Res, 2002;158:486-92.
32. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA, 2003;100:5057-62.
33. MacPhail S, Banath J, Yu Y, Chu E, Olive P. Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells. Radiat Res, 2003;159: 759-67.
34. Mirzoeva O, Petrini J. DNA replication-dependent nuclear dynamics of the Mre11 complex. Mol Cancer Res, 2003;1:207-18.
35. Rothkamm K, Kruger I, Thompson L, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol, 2003;23:5706-15.
36. MacPhail S, Banath J, Yu T, Chu E, Lambur H, Olive P. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol, 2003;79:351-8.
37. Peng J, Zhu Y, Milton J, Price D. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 1998;12:755-62.
38. Kim K, Sack J, Tokarski J, et al. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem, 2000;43:4126-34.
39. Nazarov I, Smirnova A, Krutilina R, et al. Dephosphorylation of histone γ-H2AX during repair of DNA double-strand breaks in mammalian cells and its inhibition by calyculin A. Radiat Res, 2003; 160:309-17.